Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Net Income towards Common Stockholders (2022 - 2026)

TriSalus Life Sciences has reported Net Income towards Common Stockholders over the past 5 years, most recently at $1.5 million for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders rose 113.88% year-over-year to $1.5 million; the TTM value through Mar 2026 reached -$58.5 million, down 92.95%, while the annual FY2025 figure was -$69.7 million, 109.7% down from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 was $1.5 million at TriSalus Life Sciences, up from -$9.8 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $1.9 million in Q2 2022 and troughed at -$41.3 million in Q3 2025.
  • A 5-year average of -$11.6 million and a median of -$9.2 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 1726.35% in 2023 and later skyrocketed 113.88% in 2026.
  • Year by year, Net Income towards Common Stockholders stood at -$25.4 million in 2022, then plummeted by 43.62% to -$36.4 million in 2023, then skyrocketed by 70.11% to -$10.9 million in 2024, then increased by 10.45% to -$9.8 million in 2025, then surged by 115.78% to $1.5 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for TLSI at $1.5 million in Q1 2026, -$9.8 million in Q4 2025, and -$41.3 million in Q3 2025.